Equities Analysts Set Expectations for KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Brookline Capital Management issued their FY2029 EPS estimates for shares of Kymera Therapeutics in a report released on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($6.44) per share for the year. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share.

KYMR has been the topic of a number of other research reports. BTIG Research initiated coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $60.00 price target on the stock. Stephens started coverage on shares of Kymera Therapeutics in a research report on Monday, November 18th. They set an "overweight" rating and a $65.00 target price on the stock. Guggenheim lifted their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday, November 1st. UBS Group decreased their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Finally, Morgan Stanley raised their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $55.38.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded down $0.40 during midday trading on Wednesday, reaching $40.52. 322,142 shares of the stock traded hands, compared to its average volume of 428,648. The company's 50 day moving average is $44.20 and its 200 day moving average is $43.92. Kymera Therapeutics has a one year low of $25.46 and a one year high of $53.27. The stock has a market capitalization of $2.62 billion, a PE ratio of -17.32 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same period in the prior year, the company earned ($0.90) earnings per share. The firm's revenue was down 20.9% on a year-over-year basis.

Insider Buying and Selling at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares of the company's stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.82% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp increased its holdings in Kymera Therapeutics by 19.3% during the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock valued at $4,663,000 after buying an additional 25,317 shares during the period. Rhumbline Advisers raised its position in shares of Kymera Therapeutics by 12.4% in the 2nd quarter. Rhumbline Advisers now owns 64,535 shares of the company's stock worth $1,926,000 after acquiring an additional 7,143 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Kymera Therapeutics by 15.6% during the 2nd quarter. Arizona State Retirement System now owns 12,830 shares of the company's stock worth $383,000 after purchasing an additional 1,730 shares during the last quarter. Quest Partners LLC boosted its position in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company's stock valued at $156,000 after purchasing an additional 4,865 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Kymera Therapeutics by 2.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company's stock valued at $12,115,000 after purchasing an additional 10,731 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.